Your session is about to expire
← Back to Search
tDCS for Slowing ALS Progression
Study Summary
This trial will use remotely supervised brain stimulation to attempt to preserve motor function in people with ALS.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 2 trial • 54 Patients • NCT01726673Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your ALSFRS-R score has changed by 1-2 points before joining the study.I am on a stable dose of ALS medication or not taking any.I was diagnosed with ALS less than 5 years ago.You have mental health conditions.I do not have any other serious illnesses that could affect my ALS outcome.I have been diagnosed with ALS.My neurological condition is not ALS.You have difficulty swallowing, as indicated by a score of 2 or more on the ALSFRS-R test.I use a ventilator for more than 12 hours daily.My ALS started with speech or swallowing problems.I can walk with some assistance.You are currently taking part in another clinical trial for ALS.My ALS started with weakness in my arms or legs.
- Group 1: Transcranial Direct Current Stimulation (tDCS)
- Group 2: Delayed-Start Transcranial Direct Current Stimulation (tDCS) Control Group
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are geriatric individuals being recruited for this experiment?
"This clinical trial is only open to patients aged 18-80. For those above 80 or below 18, there are 54 and 464 trials respectively catering to their age range."
How many participants have been recruited to partake in this clinical experiment?
"That is correct. Information published on clinicaltrials.gov affirms that this trial, initially posted on August 27th 2021, is currently recruiting participants. It aims to enroll 100 patients at a single medical centre."
To whom does this experiment extend an invitation?
"This double-blind trial is recruiting a cohort of 100 persons with amyotrophic lateral sclerosis aged between 18 and 80. Prospective participants must satisfy the following criteria: A definitive diagnosis according to El Escorial revised guidelines, initial muscular weakness in an upper or lower limb within 24 months prior, 1-2 point drop in ALSFRS-R pre-slope (ratio of decline from 48 to time since onset), slow vital capacity surpassing 40% predicted value, score 2+ for "swallowing" and "walking" on ALSFRS-R scale, willingness to sign informed consent form, prescribed riluzole"
What are the desired outcomes of this trial?
"This clinical trial seeks to evaluate the Revised ALS Functioning Rating Scale (ALSFRS-R). Secondary objectives include assessing fatigue severity through a 9-item scale, upper and lower motor neuron mechanisms with peripheral nerve stimulation at either the knee or elbow, as well as quality of life via EuroQol-5D (EQ-5D) questionnaires. The overall duration is Change from baseline to immediately after training and baseline to 3 months follow up.."
Are there still vacancies for participants in this research?
"Indeed, the details on clinicaltrials.gov verify that this experiment is actively enlisting patients. It was initially posted in August 27th 2021 and last updated July 6th 2022; 100 individuals are expected to join from 1 site."
Share this study with friends
Copy Link
Messenger